Gene Therapy Startups funded by Y Combinator (YC) 2026

November 2026

Browse 14 of the top Gene Therapy startups funded by Y Combinator.

We also have a Startup Directory where you can search through over 5,000 companies.

  • BioDelivera
    BioDelivera
    Y Combinator LogoF2026
    Active • 2 employees • San Francisco
    BioDelivera has developed proprietary GCV™, a drug delivery platform designed to travel through the body and selectively target diseased cells while sparing healthy ones. GCVs can carry genetic medicines, DNA, RNA, small molecules, or combinations of these at the same time. BioDelivera has demonstrated efficacy in tumors, muscle, and brain and is expanding to additional tissues. The company’s mission is to enable cures for every patient, across every disease.
    gene-therapy
    therapeutics
    drug-delivery
    biotechnology
    ai
  • FinalDose
    FinalDose
    Y Combinator LogoP2026
    Active • 5 employees • London
    FinalDose is building the first programmable drug - a single smart drug molecule that you can insert any diseased genetic code and it can search and destroy cells upon DNA recognition. Unlocking 80% of undruggable targets today. Starting with all cancers.
    gene-therapy
    therapeutics
    genetic-engineering
    ai
  • Uncommon Therapeutics
    Uncommon Therapeutics
    Y Combinator LogoW2025
    Active • 2 employees • San Francisco
    Our founder Noah, an experienced tech entrepreneur, was directly impacted by a severe genetic disease when his daughter was diagnosed with Rett Syndrome, a disease that afflicts 1 in 10,000 girls. Using an innovative polytherapy strategy, we’ve successfully improved her quality of life, and have designed new therapeutics that each could be worth billions and together could deliver a cure.
    gene-therapy
    crispr
    biotechnology
  • Kopra Bio
    Kopra Bio
    Y Combinator LogoS2024
    Active • 2 employees • San Francisco
    Kopra Bio makes genetically engineered viruses that teach your immune system to kill cancer using tech we developed at UCSF. We’re making the next Keytruda ($25B/yr cancer drug blockbuster) starting with the most aggressive form of brain cancer, glioblastoma. In the most challenging brain cancer model, we improve survival from 0% with the current FDA approved treatment to 90% with our treatment.
    gene-therapy
    synthetic-biology
    biotech
    therapeutics
    oncology
  • ParcelBio
    ParcelBio
    Y Combinator LogoW2024
    Active • 6 employees • San Francisco
    ParcelBio is engineering a new class of mRNA medicines designed to deliver unprecedented potency and durability. Its proprietary APEXm™ platform uses novel RNA domains to enhance protein expression and extend activity, enabling therapies that reach the thresholds required for meaningful, and potentially curative, clinical outcomes. The company is advancing programs in autoimmune disease, oncology, and encoded protein therapeutics.
    gene-therapy
    synthetic-biology
    biotech
    therapeutics
    drug-discovery
  • Modulari-T
    Modulari-T
    Y Combinator LogoW2023
    Active • 4 employees • Montreal, QC, Canada
    Cell and gene therapy promises to one day cure any disease; Modulari-T’s Platform produces the tools to fulfill that promise. Modulari-T has designed a new family of synthetic genes that can reprogram cells to better sense their environment and modify their behavior accordingly. This can be used to engineer immune cells to efficiently recognize and kill cancer cells or to create stem cells able to regenerate any tissue. Modulari-T looks to expand its technology to reach every area of cell therapy and become the platform of reference for cell engineering.
    gene-therapy
    cell-therapy
    synthetic-biology
    biotech
    oncology
  • Nephrogen
    Nephrogen
    Y Combinator LogoS2020
    Active • 5 employees • New York City
    Nephrogen is a Stanford biotech spin-out developing curative genetic medicines for kidney and pancreatic diseases. Kidney disease alone affects 1 in 7 Americans, and neither indication has any approved gene-based therapies. Nephrogen's underlying platform combines AI and high-throughput screening to engineer safer, more efficient, and less expensive gene delivery vehicles for reaching the kidney and pancreas, and has attracted non-dilutive funding from seven major pharmaceutical companies including Merck KGaA, Novartis, and Bristol Myers Squibb.
    gene-therapy
    crispr
    biotech
  • WhiteLab Genomics
    WhiteLab Genomics
    Y Combinator LogoW2022
    Active • 52 employees • Paris, France
    WhiteLab Genomics is a TechBio company using artificial intelligence to design the building blocks of genomic medicines. Its proprietary ALFRED platform designs viral and non-viral delivery vehicles and programmable genetic payloads, which are then experimentally validated and tested in vivo to identify candidates with the properties required for therapeutic development. Through this integrated approach, WhiteLab Genomics is building a portfolio of validated bio-assets that it advances independently and with pharmaceutical and biotechnology partners developing the next generation of genomic medicines. Founded in 2019, WhiteLab works with industrial and academic partners including Sanofi, Cytiva, the University of Massachusetts, the Vision Institute in Paris and the Paris Brain Institute, alongside additional collaborations with biotechnology companies. The company is part of Y-Combinator, Station F and Future4Care and is a French Tech 2030 laureate. WhiteLab Genomics operates from Paris, Boston, and Montreal.
    gene-therapy
    cell-therapy
    genomics
    ai
  • Andson Biotech
    Andson Biotech
    Y Combinator LogoW2022
    Active • 12 employees • Atlanta, GA, USA
    Andson Biotech helps pharmaceutical companies measure difficult to detect chemicals that they need to measure while developing and manufacturing drugs like cell-therapies or biologics. Drug companies want to use our technologies to get fast and accurate chemical measurements they do thousands of times per day for drug development and quality control.
    gene-therapy
    hard-tech
    biotech
    therapeutics
    healthcare
  • 64x Bio
    64x Bio
    Y Combinator LogoS2018
    Active • 25 employees • San Francisco
    The future of medicine is taking shape, but scaling it remains a challenge. Some of the biggest breakthroughs in next generation therapies are being held back by manufacturing constraints. The science is moving fast, but the infrastructure is still catching up. Our VectorSelect platform is designed to unlock the scale these therapies need to survive. We combine massively parallelized screens with computational insights to engineer high yield cell lines and production technologies — accelerating the manufacturing of advanced therapies from the inside out.
    gene-therapy
    machine-learning
  • Rejuvenation Technologies Inc.
    Rejuvenation Technologies Inc.
    Y Combinator LogoS2018
    Active • 7 employees • San Francisco
    Stanford-patented essential drug platform unlocks the healthspan, which is limited by short telomeres. Reverses 10 years of telomere shortening with a single dose. Preclinical efficacy in fibrotic liver and lung disease. Entering IND-enabling. 50+ granted patents, 7 patent families. FDA INTERACT cleared.
    anti-aging
    gene-therapy
    nanomedicine
  • Sixfold Bioscience
    Sixfold Bioscience
    Y Combinator LogoW2018
    Active • 27 employees • London
    Sixfold is focused on the commercialisation of its patented drug delivery systems for RNA therapeutics such as siRNAs for gene silencing and mRNAs for gene expression.
    gene-therapy
    nanomedicine
    drug-delivery
  • Indee Labs
    Indee Labs
    Y Combinator LogoW2017
    Active • 5 employees • San Francisco
    Intracellular delivery is the most problematic step in T cell immunotherapy discovery, development and manufacturing. Indee Labs is developing a non-viral intracellular delivery system based on microfluidic vortex shedding (µVS) to rapidly deliver nucleic acids, proteins and gene editing complexes to patient and donor T cells with minimal perturbation.
    gene-therapy
    microfluidics
    cell-therapy